Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000886163-25-000036
Filing Date
2025-05-09
Accepted
2025-05-09 16:04:28
Documents
75
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q lgnd-20250331.htm   iXBRL 10-Q 1091453
2 EX-2.1 exhibit21_ligand-castlecre.htm EX-2.1 638626
3 EX-31.1 lgnd_33125exhibit311.htm EX-31.1 15156
4 EX-31.2 lgnd_33125exhibit312.htm EX-31.2 15426
5 EX-32.1 lgnd_33125exhibit321.htm EX-32.1 11156
11 lgnd-20250331_g1.jpg GRAPHIC 43732
  Complete submission text file 0000886163-25-000036.txt   8842123

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20250331.xsd EX-101.SCH 57840
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lgnd-20250331_cal.xml EX-101.CAL 105068
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lgnd-20250331_def.xml EX-101.DEF 331178
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20250331_lab.xml EX-101.LAB 819447
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20250331_pre.xml EX-101.PRE 559882
78 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20250331_htm.xml XML 1070003
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33093 | Film No.: 25930265
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)